Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
Conclusion
These are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Dejaco, C., Kerschbaumer, A., Aletaha, D., Bond, M., Hysa, E., Camellino, D., Ehlers, L., Abril, A., Appenzeller, S., Cid, M. C., Dasgupta, B., Duftner, C., Grayson, P. C., Hellmich, B., Hocevar, A., Kermani, T. A., Matteson, E. L., Mollan, S. P., Neill, Tags: Open access, ARD Recommendation Source Type: research
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Conclusions
In the light of recent advancements, these recommendations provide updated guidance on AAV management. As substantial data gaps still exist, informed decision-making between physicians and patients remains of key relevance. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Hellmich, B., Sanchez-Alamo, B., Schirmer, J. H., Berti, A., Blockmans, D., Cid, M. C., Holle, J. U., Hollinger, N., Karadag, O., Kronbichler, A., Little, M. A., Luqmani, R. A., Mahr, A., Merkel, P. A., Mohammad, A. J., Monti, S., Mukhtyar, C. B., Musial, Tags: ARD, EULAR papers Recommendation Source Type: research
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Conclusion
The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S.-C., Boletis, J., Bruce, I. N., Cervera, R., Doria, A., Dörner, T., Furie, R. A., Gladman, D. D., Houssiau, F. A., Ines, L. S., Jayne, D., Kouloumas, M., Kovacs, L., M Tags: ARD, EULAR papers Recommendation Source Type: research
Long COVID: a new word for naming fibromyalgia?
In conclusion, "to name is to soothe" as said by Roland Barthes. However, "Naming things wrongly adds to the world's unhappiness" was saying Albert Camus. Thus, the term of long COVID, which suggests viral persistence of impaired immune response to the virus, is unappropriated and should be replaced by fibromyalgia-like post-COVID syndrome. Research on the psychosomatic and somatic mechanisms involved in these fibromyalgia-like post-viral syndromes must be encouraged. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Mariette, X. Tags: ARD, COVID-19 Viewpoint Source Type: research
Improving the nosology of Long COVID: it is not so simple
Long COVID is a diagnostic label currently given to those suffering from a poorly understood state of incomplete recovery or who have development of a myriad of medically unexplained symptoms occurring in the wake of infection with SARS CoV-2 that is both poorly understood and controversial. Many of the features of one of the most common clinical endotypes of Long COVID are shared by a condition well familiar to all rheumatologists and one with a large body of epidemiologic, clinical and basic research accrued over many decades namely the syndrome of fibromyalgia. Some have recently suggested that Long COVID may merely be ...
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Calabrese, L. H., Mease, P. J. Tags: ARD, COVID-19 Viewpoint Source Type: research
Annals of the Rheumatic Diseases collection on glucocorticoids (2020-2023): novel insights and advances in therapy
Discussion on an acceptable balance between efficacy and safety of (often low dose) GCs in the treatment of inflammatory rheumatic diseases is as old as the treatment itself. During the period 2020–2023, Annals of the Rheumatic Diseases published several original papers, brief reports and letters that further elucidate the mechanisms of action and especially advances in the clinical application of GC therapy. A selection of representative original papers is highlighted below. Mechanisms of action GCs regulate... (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Bijlsma, J. W. J. Tags: ARD Editorials Source Type: research
Correction: Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot collaboration
Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration. Annals of the Rheumatic Diseases 2022;81:1358-66.
The scale limit setting in figure 3 has an error, resulting in the omission of two bar plots.
The corrected figure 3 is below:
doi:10.1136/ard-2022–2 22 586 (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Tags: Open access, ARD Correction Source Type: research
Greetings from the editor 2024
Over the last years, several of the New Year-Greetings to the readership have addressed anniversaries. While in 2019 Annals of the Rheumatic Diseases (ARD) reached its 80th anniversary and 2020 marked the 20th anniversary of ARD becoming the EULAR journal,1 EULAR itself celebrated its 75th birthday 2 years ago.2 The year 2024 marks even a whole set of anniversaries. This time they deal with therapeutic breakthroughs that have changed rheumatology significantly over the past decades. Indeed, the consequences of the discoveries that stand behind these breakthroughs demand a look into history so we can appreciate and celebrat...
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Smolen, J. S. Tags: ARD Editorials Source Type: research
News from EULAR
EULAR’s new strategy for 2024–2028 European Alliance of Associations for Rheumatology (EULAR) is excited to announce a new and innovative step in its mission to minimise the impact of rheumatic and musculoskeletal diseases (RMDs) on individuals and societies. EULAR focuses on creating global awareness and providing solutions for the management of RMDs through cutting-edge innovation in research, patient empowerment and expert collaboration. Read more about EULAR Strategy 2024 - 2028 %7C EULAR The latest recommendations from EULAR EULAR recommendations for the use of imaging in large vessel vasculitis in clinica...
Source: Annals of the Rheumatic Diseases - November 10, 2023 Category: Rheumatology Authors: EULAR Communications Tags: ARD Eular news Source Type: research
Anti-cyclic citrullinated peptide antibody and pain sensitisation in patients with rheumatoid arthritis: a cross-sectional analysis
Pain and inflammation are often discordant among patients with rheumatoid arthritis (RA). In a mouse model, systemic injection of polyclonal autoantibodies against citrullinated proteins (ACPA) induced pain-like behaviours.1 A recent study also suggested that specific monoclonal ACPAs may be responsible for tenosynovitis and pain behaviours in mice.2 Given these findings, our goal was to examine the association between a subset of ACPA, anti-cyclic citrullinated peptides (anti-CCP) and pain in humans with RA. Patients with active RA were enrolled in the Central Pain in RA study. Anti-CCP positivity was categorised as posit...
Source: Annals of the Rheumatic Diseases - November 10, 2023 Category: Rheumatology Authors: Qiu, Y. Y., Neogi, T., Muhammad, L. N., Song, J., Bolster, M. B., Marder, W., Heisler, A. C., Wohlfahrt, A., Dunlop, D., Lee, Y. C. Tags: ARD Letter Source Type: research
Low avidity observed for anti-citrullinated peptide antibody is not a general phenomenon for autoantibodies
Anti-citrullinated protein antibody (ACPA) is specifically detected in patients with rheumatoid arthritis (RA) preceding disease onset. Hence, understanding the mechanism of ACPA production is important for elucidating the aetiology of RA. The avidity of serum antibody to an antigen increases with time, affinity maturation, in which B cells bearing high-affinity receptor generated via somatic hyper mutation (SHM) are selected in the germinal centre. However, it has been reported that the avidity of ACPA is lower than antibodies against recall antigens,1 although the underlying mechanism remains unclear. One possibility is ...
Source: Annals of the Rheumatic Diseases - November 10, 2023 Category: Rheumatology Authors: Yamada, H., Haraguchi, A., Tsuru, T., Kondo, M., Sagawa, F., Niiro, H., Nakashima, Y. Tags: ARD Letter Source Type: research
Finger ischaemia, enlarged spleen and lung nodules
A 48-year-old man presented with a 10 kg weight loss and fever. On examination, there was digital ischaemia (figure 1), oedema of the lower extremities and absence of heart murmur. Laboratory investigation showed anaemia with a haemoglobin concentration of 96 g/L, thrombocytosis (995 Giga/L) and raised cardiac troponin T values (10 500 ng/L; normal 0–14). Howell-Jolly bodies were present on a blood smear (nuclear remnants found in red blood cells consistent with hyposplenism). Kidney function was normal with a serum creatinine level of 56 µmol/L, but the patient had haematuria on urine examination. PR3-ANCA was...
Source: Annals of the Rheumatic Diseases - November 10, 2023 Category: Rheumatology Authors: Puechal, X., Delaval, L., Blanche, P. Tags: ARD, Images in rheumatology Source Type: research
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial
Conclusions
Placebo is not non-inferior to colchicine in prevention of gout flares in the first 6 months of starting allopurinol using the ‘start-low go-slow’ strategy. After stopping colchicine, gout flares rise with no difference in the mean number of gout flares/month between groups over a 12-month period.
Trial registration number
ACTRN 12618001179224. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - November 10, 2023 Category: Rheumatology Authors: Stamp, L., Horne, A., Mihov, B., Drake, J., Haslett, J., Chapman, P. T., Frampton, C., Dalbeth, N. Tags: ARD Lay summaries, ARD, Crystal arthropathies Source Type: research
Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink
Conclusions
Adverse events were more common when allopurinol was initiated with prophylaxis, particularly diarrhoea with colchicine. Other events were uncommon, providing reassurance for patients and clinicians to enable shared decision-making. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - November 10, 2023 Category: Rheumatology Authors: Roddy, E., Bajpai, R., Forrester, H., Partington, R. J., Mallen, C. D., Clarson, L. E., Padmanabhan, N., Whittle, R., Muller, S. Tags: Open access, ARD, Crystal arthropathies Source Type: research
Evaluating the causal effect of circulating proteome on the risk of osteoarthritis-related traits
Conclusions
Through MR analysis, we have identified numerous plasma proteins associated with OA-related traits, shedding light on protein-mediated mechanisms and offering promising therapeutic targets for OA. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - November 10, 2023 Category: Rheumatology Authors: Zhang, Y., Xie, J., Wen, S., Cao, P., Xiao, W., Zhu, J., Li, S., Wang, Z., Cen, H., Zhu, Z., Ding, C., Ruan, G. Tags: ARD, Osteoarthritis Source Type: research
